Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex

View ORCID ProfileChapin S. Korosec, View ORCID ProfileSuzan Farhang-Sardroodi, David W. Dick, Samaneh Gholami, Mohammad Sajjad Ghaemi, View ORCID ProfileIain R. Moyles, View ORCID ProfileMorgan Craig, View ORCID ProfileHsu Kiang Ooi, View ORCID ProfileJane M. Heffernan
doi: https://doi.org/10.1101/2021.10.13.21264957
Chapin S. Korosec
1Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
2Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chapin S. Korosec
  • For correspondence: chapinSkorosec@gmail.com
Suzan Farhang-Sardroodi
1Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
2Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Suzan Farhang-Sardroodi
David W. Dick
1Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
2Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samaneh Gholami
1Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
2Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Sajjad Ghaemi
3Digital Technologies Research Centre, National Research Council Canada, Toronto, ON C1A 4P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iain R. Moyles
2Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Iain R. Moyles
Morgan Craig
4Sainte-Justine University Hospital Research Centre and Department of Mathematics and Statistics, Université de Montréal, Montreal, QC H3T 1J4, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Morgan Craig
Hsu Kiang Ooi
3Digital Technologies Research Centre, National Research Council Canada, Toronto, ON C1A 4P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hsu Kiang Ooi
Jane M. Heffernan
1Modelling Infection and Immunity Lab, Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
2Centre for Disease Modelling (CDM), Mathematics Statistics, York University, Toronto, ON M3J 1P3, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jane M. Heffernan
  • For correspondence: jmheffer@yorku.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The lipid nanoparticle (LNP)-formulated mRNA vaccines are a widely adopted two-dose vaccination public health strategy to manage the COVID-19 pandemic. Clinical trial data has described the immunogeneicity of the vaccine, albeit within a limited study time frame. Our aims were to use a within-host mathematical model for LNP-formulated mRNA vaccines, informed by available clinical trial data, to project a longer term understanding of humoral immunity as a function of vaccine type, dosage amount, age, and sex.

Methods We developed a mathematical model describing the immunization process of LNP-formulated mRNA vaccines, and fit our model to twenty-two clinical humoral and cytokine BNT162b2 or mRNA-1273 human two-dose vaccination data sets. We incorporated multi-dose effects in our model to specify whether the dosage is standard or low-dose. We further specify the age groups 18-55, 56-70, and 70+ in our fits for two-standard doses of mRNA-1273, and sex in our fits for two-standard doses of BNT162b2. We used non-linear mixed effect models to fit to all similar data types (e.g. standard two-dose BNT162b2 or mRNA-1273, or two low-dose mRNA-1273). Therefore, in our fits all estimated parameters are statistically correlated, which allowed us to determine the underlying ‘population-dynamics’ structure common to a data type. We therefore made accurate long-term predictions informed by all clinical data used in this study.

Findings We estimate that two standard doses of either mRNA-1273 or BNT162b2, with dosage times separated by the company-mandated intervals, results in individuals loosing more than 99% humoral immunity relative to peak immunity by eight months following the second dose. We predict that within an eight month period following dose two (corresponding to the CDC time-frame for administration of a third dose), there exists a period of time longer than one month where an individual has less then 99% humoral immunity relative to peak immunity, regardless of which vaccine was administered. We further find that age has a strong influence in maintaining humoral immunity; by eight months following dose two we predict that individuals aged 18-55 have a four-fold humoral advantage compared to aged 56-70 and 70+ individuals. We find that sex has little effect on the vaccine uptake and long-term IgG counts. Finally, we find that humoral immunity generated from two low doses of mRNA-1273 decays substantially slower relative to peak immunity gained than compared to two standard doses of either mRNA-1273 or BNT162b2.

Interpretation For the two dose mRNA vaccines, our predictions highlight the importance of the recommended third booster dose in order to maintain elevated levels of antibodies. We further show that age plays a critical role in determining the antibody levels. Hence, a third booster dose may confer an immuno-protective advantage in older individuals.

Funding This research is supported by NSERC Discovery Grant (RGPIN-2018-04546), NSERC COVID-19 Alliance Grant ALLRP 554923-20, CIHR-Fields COVID Immunity Task Force, NRC Pandemic Response Challenge Program Grant No. PR016-1.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

his research is supported by NSERC Discovery Grant (RGPIN-2018-04546), NSERC COVID-19 Alliance Grant ALLRP 554923-20, CIHR-Fields COVID Immunity Task Force, NRC Pandemic Response Challenge Program Grant No. PR016-1.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

[1] https://pubmed.ncbi.nlm.nih.gov/33858945/ [2] https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab555/6301133 [3] https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00932-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124721009323%3Fshowall%3Dtrue [4] https://doi.org/10.1101/2021.03.22.436441 [5] DOI: 10.1056/NEJMc2032195 [6] https://www.nature.com/articles/s41586-021-03324-6 [7] https://www.biorxiv.org/content/10.1101/2021.09.30.462488v1 [8] https://www.science.org/doi/10.1126/science.abj9853

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 18, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Chapin S. Korosec, Suzan Farhang-Sardroodi, David W. Dick, Samaneh Gholami, Mohammad Sajjad Ghaemi, Iain R. Moyles, Morgan Craig, Hsu Kiang Ooi, Jane M. Heffernan
medRxiv 2021.10.13.21264957; doi: https://doi.org/10.1101/2021.10.13.21264957
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Chapin S. Korosec, Suzan Farhang-Sardroodi, David W. Dick, Samaneh Gholami, Mohammad Sajjad Ghaemi, Iain R. Moyles, Morgan Craig, Hsu Kiang Ooi, Jane M. Heffernan
medRxiv 2021.10.13.21264957; doi: https://doi.org/10.1101/2021.10.13.21264957

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2467)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4844)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)